Agilent Technologies
Investments
32Portfolio Exits
11Partners & Customers
10About Agilent Technologies
Agilent Technologies (NYSE: A) provides instruments, software, services, and consumables for the entire laboratory workflow, serving the life sciences, diagnostics, and applied chemical markets. The company was founded in 1999 and is based in Santa Clara, California.
Expert Collections containing Agilent Technologies
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Agilent Technologies in 3 Expert Collections, including Synthetic Biology.
Synthetic Biology
382 items
Medical Devices
3,868 items
https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.
Health Monitoring & Diagnostics
76 items
Companies developing companion diagnostics and technology enabling the development of companion diagnostics. Tagged as #CompanionDx
Research containing Agilent Technologies
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Agilent Technologies in 1 CB Insights research brief, most recently on Sep 12, 2022.
Latest Agilent Technologies News
Aug 16, 2023
| AlphaStreet Views: 1 Agilent Technologies (NYSE: A) on Tuesday reported mixed results for the third quarter of 2023 when the medical device company’s adjusted earnings increased despite a drop in revenues. The Santa Clara-based company said its third-quarter profit, on an adjusted basis, rose to $1.43 per share from $1.34 per share in the year-ago period. Unadjusted net income was $111 million or $0.38 per share in Q3, compared to $329 million or $1.10 per share in the corresponding quarter of 2022. At $1.67 billion, revenues were down 2.7% from last year. “Looking forward, we believe the current market environment is transitory, and are confident in our team and the long-term growth prospects of our end markets,” said Agilent’s CEO Mike McMullen. Prior Performance
Agilent Technologies Investments
32 Investments
Agilent Technologies has made 32 investments. Their latest investment was in Halo Labs as part of their Series C on July 7, 2022.
Agilent Technologies Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
7/11/2022 | Series C | Halo Labs | $6M | Yes | Agilent Technologies, BioAdvance, BroadOak Capital Partners, Research Corporation Technologies, Undisclosed Angel Investors, and Undisclosed Investors | 7 |
3/15/2022 | Series B | Arima Genomics | $7M | Yes | 6 | |
3/15/2022 | Series B - II | Molecular Assemblies | $25.8M | No | 4 | |
1/11/2022 | Series A | |||||
12/16/2021 | Series A - II |
Date | 7/11/2022 | 3/15/2022 | 3/15/2022 | 1/11/2022 | 12/16/2021 |
|---|---|---|---|---|---|
Round | Series C | Series B | Series B - II | Series A | Series A - II |
Company | Halo Labs | Arima Genomics | Molecular Assemblies | ||
Amount | $6M | $7M | $25.8M | ||
New? | Yes | Yes | No | ||
Co-Investors | Agilent Technologies, BioAdvance, BroadOak Capital Partners, Research Corporation Technologies, Undisclosed Angel Investors, and Undisclosed Investors | ||||
Sources | 7 | 6 | 4 |
Agilent Technologies Portfolio Exits
11 Portfolio Exits
Agilent Technologies has 11 portfolio exits. Their latest portfolio exit was Cardea Bio on May 02, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
5/2/2023 | Acquired | 8 | |||
11/28/2022 | Acquired | 7 | |||
4/16/2021 | IPO | Public | 1 | ||
Date | 5/2/2023 | 11/28/2022 | 4/16/2021 | ||
|---|---|---|---|---|---|
Exit | Acquired | Acquired | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 8 | 7 | 1 |
Agilent Technologies Acquisitions
36 Acquisitions
Agilent Technologies acquired 36 companies. Their latest acquisition was e-MSion on March 09, 2023.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
3/9/2023 | Acquired | 3 | ||||
1/4/2023 | Acquired | 4 | ||||
8/2/2022 | Acquired | 1 | ||||
3/2/2021 | ||||||
7/11/2019 |
Date | 3/9/2023 | 1/4/2023 | 8/2/2022 | 3/2/2021 | 7/11/2019 |
|---|---|---|---|---|---|
Investment Stage | |||||
Companies | |||||
Valuation | |||||
Total Funding | |||||
Note | Acquired | Acquired | Acquired | ||
Sources | 3 | 4 | 1 |
Agilent Technologies Partners & Customers
10 Partners and customers
Agilent Technologies has 10 strategic partners and customers. Agilent Technologies recently partnered with Imperial College London on May 5, 2023.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
5/23/2023 | Partner | United Kingdom | Imperial and Agilent renew partnership for flagship analytical science facility Imperial College London and Agilent Technologies have announced the extension of their partnership to support advanced analytical science . | 2 | |
4/12/2023 | Licensor | United States | Further , through this partnership , Agilent Technologies Inc. may also commercialize additional algorithms PathAI launches in the future . | 3 | |
4/12/2023 | Partner | United States | `` This partnership brings together our exceptional assay development capabilities , PathAI 's expertise in digital algorithms , and Agilent Technologies Inc. 's workflow expertise to offer research , translational medicine , and diagnostics solutions of the future . '' | 1 | |
3/14/2023 | Licensee | ||||
3/10/2023 | Supplier |
Date | 5/23/2023 | 4/12/2023 | 4/12/2023 | 3/14/2023 | 3/10/2023 |
|---|---|---|---|---|---|
Type | Partner | Licensor | Partner | Licensee | Supplier |
Business Partner | |||||
Country | United Kingdom | United States | United States | ||
News Snippet | Imperial and Agilent renew partnership for flagship analytical science facility Imperial College London and Agilent Technologies have announced the extension of their partnership to support advanced analytical science . | Further , through this partnership , Agilent Technologies Inc. may also commercialize additional algorithms PathAI launches in the future . | `` This partnership brings together our exceptional assay development capabilities , PathAI 's expertise in digital algorithms , and Agilent Technologies Inc. 's workflow expertise to offer research , translational medicine , and diagnostics solutions of the future . '' | ||
Sources | 2 | 3 | 1 |
Agilent Technologies Team
21 Team Members
Agilent Technologies has 21 team members, including current Managing Director, David Hwang.
Name | Work History | Title | Status |
|---|---|---|---|
David Hwang | Managing Director | Current | |
Name | David Hwang | ||||
|---|---|---|---|---|---|
Work History | |||||
Title | Managing Director | ||||
Status | Current |
Compare Agilent Technologies to Competitors
Caris provides artificial intelligence integrated molecular science technology that assesses deoxyribonucleic acid, Ribonucleic acid, and proteins to reveal a molecular blueprint that allows physicians and cancer patients to make personalized treatment decisions. It also researches and develops molecular profiling of blood and tissues. The company was founded in 2008 and is based in Irving, Texas.
The firm aims to help the company's customers create the most productive and cost-effective thin-film applications possible - by delivering the world's most advanced magnetrons, a range of deposition materials, and a program of technical support.
SantoLubes is a chemical manufacturer that manufactures and supplies santovac, santotrac, santolube, synthetic fluids, greases, and electronic lubricants for the aviation, aerospace, and electronics sectors. It is located in Spartanburg, South Carolina.
Digistain applies machine learning algorithms to facilitate the provision of personalized risk reports to breast cancer patients and their physicians, helping reduce the timing and cost of treatment decisions, such as the need for chemotherapy. The platform technology uses infrared light to detect chemical changes occurring in tumor samples which can accompany the progression of the breast cancer disease. The company was founded in 2020 and is based in London, England.
LS CancerDiag is committed to reducing cancer mortality rates with a low-cost, simple diagnostic method that detects an inherited cancer-causing condition prior to cancer. The company's flagship product, DiagMMR assay is an easy functional test that can be used for diagnosis of MMR deficiency i.e. Lynch syndrome (previously known as Hereditary NonPolyposis Colorectal Cancer; HNPCC).
Auspex Diagnostics ceased operations. It provides artificial intelligence (AI) based advanced cancer diagnostics services intended to improve the quality of cancer care. The company's machine learning (ML) algorithm analyzes the genomic information of a patient's tumor sample and accurately assesses the risk of recurrence and drug efficacy, enabling the oncologists and patients to make the optimal data-driven decisions and personalize the treatment plan. It was founded in 2012 and is based in Warren, New Jersey.
Loading...